SUBSTRATE WITH CHANNELS FOR CONTROLLED FLUID FLOW IN BIOLOGICAL ASSAY SAMPLING
Immunoassay devices with plurality of fluid flow channels that are discrete and designed for optimal fluid control are described. Substrates configured to control the rate of fluid flow for in-situ immunoassay measurements to detect and quantify the presence of one or more analytes of interest in a sample are also described. More specifically, the present disclosure relates to consumables for lateral flow assays, which in conjunction with an instrument detect markers or causative agents of medical conditions.
1 . A device, comprising:
a single, unitary substrate comprising a plurality of discrete fluid flow channels,
a single sample zone on the substrate that is common to each fluid flow channel such that each fluid flow channel is in direct fluid communication with the sample zone at a channel entrance region of each fluid flow channel;
each fluid flow channel having a length and a width, each fluid flow channel comprising a capture zone downstream from the channel entrance region and a channel constriction zone positioned between the channel entrance region and the capture zone, the channel constriction zone having a width and a length, the channel constriction zone width corresponding to a value in the range determined by (i) a minimum value that is equal to or greater than a diameter of a particulate reagent deposited on or to be deposited on the substrate or (i′) a minimum value that is equal to or greater than about 25% of the fluid flow channel width, and (ii) a maximum value that is equal to or less than about 75% of the fluid flow channel width.
2 . The device of claim 1 , wherein the channel constriction zone length corresponds to a value in the range determined by (i) a minimum value that is equal to or greater than about 8% of the fluid flow channel length, and (ii) a maximum value that is equal to or less than about 75% of the fluid flow channel length.
3 . The device of claim 1 , wherein the channel constriction zone length corresponds to a value in the range determined by (i) a minimum value that is equal to or greater than about 10% of the fluid flow channel length, and (ii) a maximum value that is equal to or less than about 65% of the fluid flow channel length.
4 . The device of claim 1 , wherein the channel constriction zone width is variable along the channel constriction zone length.
5 . The device of claim 4 , wherein the channel constriction zone includes a taper region at an entrance region into the channel constriction zone or at an exit region of the channel constriction zone.
6 . The device of claim 5 , wherein the taper region extends from the fluid flow channel width to the channel constriction zone width.
7 . The device of claim 1 , wherein the channel constriction zone is non-angular along its length.
8 . The device of claim 1 , wherein the particulate reagent is an optically detectable solid particle.
9 . The device of claim 8 , wherein the solid particle is a fluorescent particle having a diameter of between about 0.05-750 microns (0.00005-0.75 mm).
10 . The device of claim 8 , wherein the solid particle is a fluorescent particle having a diameter of between about 0.05-10 microns (0.00005-0.01 mm).
11 . The device of claim 1 , further comprising an entrance constriction region in each fluid flow channel, the entrance constriction region positioned between the common sample zone and the channel constriction zone.
12 . The device of claim 11 , wherein the entrance constriction region is positioned at the channel entrance region.
13 . The device of claim 11 , wherein the entrance constriction region has a width and a length, wherein the entrance constriction region width is essentially the same as the channel constriction zone.
14 . The device of claim 11 , wherein the entrance constriction region is angular.
15 . The device of claim 14 , wherein the entrance constriction region comprises an angle that is between about 30-90°.
16 . The device of claim 14 , wherein the entrance constriction region has a geometric shape of a half-rhombus, half-rectangle, half-square, quarter-square, quarter-rectangle, half-parallelogram, quarter-parallelogram, or half-kite.
17 . The device of claim 11 , wherein the entrance constriction region is non-angular.
18 . The device of claim 1 , wherein the plurality of discrete fluid flow channels comprises n fluid flow channels, where n is between 2-20.
19 . The device of claim 18 , wherein each fluid flow channel n is identified by an integer between 1 and n, and wherein fluid flow channel l and fluid flow channel n each comprise an outer channel wall with a width w and a barrier extension region positioned at the channel entrance region with a width of between about w and about 10 w.
20 . The device of claim 19 , wherein the barrier extension region has a width between about w and about 5 w.
21 . The device of claim 1 , wherein the substrate is nitrocellulose.
22 . The device of claim 1 , wherein each capture zone comprises a different capture reagent.
23 . The device of claim 22 , wherein each capture zone comprises a capture reagent for an infectious agent.
24 . The device of claim 23 , wherein the infectious agent is selected from respiratory syncytial virus, influenza A virus, influenza B virus, and human metapneumovirus.
25 . The device of claim 23 , wherein the infectious agent is a Borrelia species.
26 . The device of claim 23 , wherein each capture zone comprises a capture reagent for a drug of abuse.
27 . The device of claim 26 , wherein the drug of abuse is selected from fentanyl, buprenorphine, oxycodone, and 7-aminoclonazepam.
28 . The device of claim 22 , wherein each capture zone comprises a capture reagent to discriminate bacterial from viral infection.
29 . The device of claim 28 , wherein the capture reagent comprises a reagent that binds or interacts with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), C-reactive protein (CRP), interferon-gamma-induced protein-10 (IP-10), Radical S-Adenosyl Methionine Domain Containing 2 (RSAD2), MX dynamin like GTPase 1 (MX1 or MxA), MX dynamin like GTPase 2 (MX2 or MxB), neutrophil gelatinase-associated lipocalin (NGAL), and procalcitonin (PCT).
30 . The device of claim 22 , wherein the capture reagent is a (i) monoclonal or a polyclonal antibody, (ii) a fragment of TRAIL, CRP, IL-10, RSAD2, MX1, MX2, NGAL, PCT or (iii) a fragment of an infectious agent.
31 . The device of claim 1 , wherein the substrate is a laminate comprising a hydrophobic material.
32 . A method of diagnosing, treating, or both a condition or disorder in a subject, comprising:
providing a device of any preceding claim,
contacting the device with a biological sample from the subject; and
determining presence or absence of the condition or disorder, and
optionally, diagnosing the condition or disorder, and
optionally treating the condition or disorder with a suitable therapeutic agent.
33 . The method of claim 32 , wherein the condition or disorder is a bacterial infection, a viral infection, or an addiction or misuse of a drug.
34 . The method of claim 33 , wherein the viral infection is a respiratory infection.
35 . The method of claim 33 , wherein the bacterial infection is Lyme disease or sepsis.
36 . The method of any one of claims 32 , wherein treating the condition or disorder with a suitable therapeutic agent comprises treating with an antibiotic.